| ObjectiveTo observe the clinical efficacy and adverse reactions of patients with intermediate and advanced colorectal cancer treated with Jianshu Detoxification and Tongluo Formula combined with Tegafur,and to provide clinical evidence for the maintenance treatment of intermediate and advanced colorectal cancer by using single and multifactorial analysis of the prognostic factors affecting patients’ PFS and OS.MethodsThirty-three patients with mid-to late-stage(stage IIB-IIIC)colorectal cancer who underwent radical surgery for colorectal cancer,had a clear pathological diagnosis,and were treated with maintenance therapy after chemotherapy with the Spleen Detoxification and Tongluo Formula combined with Tegafur from October 2017 to February 2021 were recruited from the Department of Integrative Medicine and Oncology of the First Affiliated Hospital of Anhui Medical University.All patients could selectively receive our agreed formula(Jianshu Tongluo Detoxification Formula)plus and minus treatment.The KPS,DFS,OS and toxic side effects of the patients were observed.The Kaplan-Meier method was used to analyze the median survival and survival graph,and the Log-rank test was used to analyze the factors affecting the patients’ DFS and OS,and then the independent factors affecting DFS and OS were further summarized by Cox proportional risk model.ResultsOf the 33 clinical data included in the study,4 patients died and 29 patients have survived to date.1.In terms of KPS: Among the 33 patients,KPS improved in 16 cases,KPS was stable in 9 cases,and KPS was ineffective in 8 cases.The overall stability rate(improvement + stability)of patients’ quality of survival after maintenance treatment was75.8%.2.DFS: The mean DFS of the patients with colorectal cancer included in the study was 28.536±4.431 months.22 of 33 patients(66.7%)had DFS greater than 1 year,11patients(33.3%)had DFS greater than 2 years,5 patients(15.2%)had DFS greater than3 years,and 3 patients(9.1%)had DFS greater than 5 years.As for OS: The mean OS of patients with gastric cancer included in the study was46.106±4.582 months.33 patients(100%)survived for more than 1 year,30 patients(90.1%)survived for more than 2 years,13 patients(39.4%)survived for more than 3years,and 3 patients(9.1%)survived for more than 5 years.4.In terms of prognostic factors: this study explored from multiple factors,and the results suggested that the admission KPS score and whether weight gain were factors affecting DFS.After COX regression analysis,weight(P=0.004,Exp(B)=0.430)and admission KPS score(P=0.002,Exp(B)=0.228)were statistically significant(P<0.05)and were independent factors influencing DFS,and they were positively correlated(B values were all greater than 0).The KPS score for admission(P=0.027,Exp(B)=0.922).The admission KPS score was a factor affecting OS.Adverse effects: 33 patients tolerated tegafur well,1 patient had mild-moderate skin reaction(pruritus);1 patient had mild nausea,so all patients had serious adverse effects.Conclusion1.the treatment modality of strengthening the spleen,detoxifying and tonifying formula combined with tegafur can improve the quality of patients’ survival and prolong the disease-free survival of the disease with little adverse effects.2.This maintenance treatment regimen is safe,effective and easy to accept for patients with mid-to late-stage colorectal cancer,and is worthy of further study and promotion. |
PDF Full Text Request